# Study of KN026 Combined With KN046 in Patients With Locally Advanced HER2-positive Solid Tumors

> **NCT04521179** · PHASE2 · COMPLETED · sponsor: **Jiangsu Alphamab Biopharmaceuticals Co., Ltd** · enrollment: 102 (actual)

## Conditions studied

- HER2-positive Solid Tumors

## Interventions

- **DRUG:** KN026 combination

## Key facts

- **NCT ID:** NCT04521179
- **Lead sponsor:** Jiangsu Alphamab Biopharmaceuticals Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-12-07
- **Primary completion:** 2022-01-12
- **Final completion:** 2023-05-22
- **Target enrollment:** 102 (ACTUAL)
- **Last updated:** 2023-09-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04521179

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04521179, "Study of KN026 Combined With KN046 in Patients With Locally Advanced HER2-positive Solid Tumors". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04521179. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*